Building a blueprint to diagnose asymptomatic patients earlier

The client was preparing to launch a new treatment that could delay the progression of an autoimmune disease if used in its early stages. The challenge was how to get patients into screening when they were asymptomatic, with no precedent for proactive screening in the category, and no clear model for shifting .

We brought the client’s existing research into a single knowledge base, filled the gaps with qualitative interviews and AI-driven synthesis, and pinpointed the moments along the patient journey where intervention could make a real difference.

We also drew on earlier-detection programmes from other diseases, grounding our recommendations in approaches already proven to work. Interactive workshops then gave stakeholders the space to pressure-test and refine the ideas together.

The project produced an end-to-end patient journey blueprint, which became a shared reference point that helped global and local teams agree on where to intervene. Behavioural insights translated directly into practical campaigns for HCPs and the general public.

Earlier diagnosis is now a real, achievable growth opportunity rather than a theoretical ambition.